ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,736,313 | -40.5% | 131,301 | -31.7% | 0.00% | -50.0% |
| Q2 2023 | $4,601,058 | +60.6% | 192,111 | +26.2% | 0.00% | +100.0% |
| Q1 2023 | $2,864,423 | -11.0% | 152,201 | -24.7% | 0.00% | 0.0% |
| Q4 2022 | $3,219,040 | +29.3% | 202,201 | +32.9% | 0.00% | 0.0% |
| Q3 2022 | $2,490,000 | +4.3% | 152,201 | -10.2% | 0.00% | 0.0% |
| Q2 2022 | $2,388,000 | -35.8% | 169,501 | +10.4% | 0.00% | 0.0% |
| Q1 2022 | $3,720,000 | -21.6% | 153,601 | -24.4% | 0.00% | -50.0% |
| Q4 2021 | $4,744,000 | +3.1% | 203,250 | -26.6% | 0.00% | 0.0% |
| Q3 2021 | $4,602,000 | +22.2% | 277,050 | +79.4% | 0.00% | 0.0% |
| Q2 2021 | $3,766,000 | +72.0% | 154,390 | +82.0% | 0.00% | +100.0% |
| Q1 2021 | $2,189,000 | -63.5% | 84,829 | -24.4% | 0.00% | -66.7% |
| Q4 2020 | $5,998,000 | +84.3% | 112,198 | +42.2% | 0.00% | +50.0% |
| Q3 2020 | $3,255,000 | -26.8% | 78,899 | -14.0% | 0.00% | -33.3% |
| Q2 2020 | $4,448,000 | -56.5% | 91,770 | -62.0% | 0.00% | -57.1% |
| Q1 2020 | $10,215,000 | -2.6% | 241,769 | -1.3% | 0.01% | +16.7% |
| Q4 2019 | $10,484,000 | +35.8% | 245,069 | +14.3% | 0.01% | +20.0% |
| Q3 2019 | $7,719,000 | +76.4% | 214,489 | +31.0% | 0.01% | +66.7% |
| Q2 2019 | $4,376,000 | +5.8% | 163,699 | +6.3% | 0.00% | 0.0% |
| Q1 2019 | $4,135,000 | +14.3% | 153,999 | -31.2% | 0.00% | 0.0% |
| Q4 2018 | $3,618,000 | +19.1% | 223,740 | +52.9% | 0.00% | +50.0% |
| Q3 2018 | $3,038,000 | +35.9% | 146,340 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $2,235,000 | -1.1% | 146,340 | +45.5% | 0.00% | 0.0% |
| Q1 2018 | $2,260,000 | -23.6% | 100,596 | +2.3% | 0.00% | 0.0% |
| Q4 2017 | $2,959,000 | -20.2% | 98,287 | -0.2% | 0.00% | -33.3% |
| Q3 2017 | $3,708,000 | +35.0% | 98,437 | -0.1% | 0.00% | +50.0% |
| Q2 2017 | $2,747,000 | -38.0% | 98,495 | -23.5% | 0.00% | -50.0% |
| Q1 2017 | $4,428,000 | +19.1% | 128,807 | -0.1% | 0.00% | +33.3% |
| Q4 2016 | $3,718,000 | -9.6% | 128,927 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $4,115,000 | -5.6% | 129,370 | -3.6% | 0.00% | -25.0% |
| Q2 2016 | $4,358,000 | -15.5% | 134,270 | -27.2% | 0.00% | 0.0% |
| Q1 2016 | $5,160,000 | -90.6% | 184,560 | -88.0% | 0.00% | -91.5% |
| Q4 2015 | $54,934,000 | +17.6% | 1,540,932 | +9.1% | 0.05% | +17.5% |
| Q3 2015 | $46,694,000 | +641.3% | 1,411,978 | +838.8% | 0.04% | +700.0% |
| Q2 2015 | $6,299,000 | +28.5% | 150,400 | 0.0% | 0.01% | +25.0% |
| Q1 2015 | $4,902,000 | +2.9% | 150,400 | +0.3% | 0.00% | 0.0% |
| Q4 2014 | $4,763,000 | +25.4% | 150,000 | -2.2% | 0.00% | +33.3% |
| Q3 2014 | $3,798,000 | +9.6% | 153,400 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $3,465,000 | -7.2% | 153,400 | -0.0% | 0.00% | 0.0% |
| Q1 2014 | $3,734,000 | +1.2% | 153,469 | +3.9% | 0.00% | 0.0% |
| Q4 2013 | $3,691,000 | -9.0% | 147,716 | -0.0% | 0.00% | -25.0% |
| Q3 2013 | $4,058,000 | +66.7% | 147,722 | +10.1% | 0.00% | +33.3% |
| Q2 2013 | $2,434,000 | – | 134,121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |